ESK-001 + rabeprazole

ESK-001 + rabeprazole is a combination of two distinct agents: ESK-001, a highly selective oral, allosteric inhibitor of tyrosine kinase 2 (TYK2), and rabeprazole, a proton pump inhibitor (PPI) commonly used to decrease gastric acid secretion. ESK-001 is developed for immune-mediated diseases and disrupts proinflammatory cytokine signaling, notably affecting interleukin (IL)-12, IL-23, and type I interferon (IFN) pathways. It shows efficacy and safety in clinical trials for plaque psoriasis and systemic lupus erythematosus. Rabeprazole is typically used to prevent or treat gastrointestinal irritation that may be associated with some oral medications, but no clinical data were found regarding the specific combined use of ESK-001 with rabeprazole as a single product. This entry refers to the co-administration of both drugs, likely intended as a supportive regimen in clinical studies or in clinical practice for side effect management related to ESK-001's oral formulation[1][2][5].